Patheon mulls drug delivery tech deals to accelerate development services growth

By Nick Taylor

- Last updated on GMT

Related tags Technology Patheon

Patheon is considering buying unique drug delivery technologies to expand its development service capabilities.

In September Patheon highlighted investment in development services as part of its strategy to improve on “poor historical performance​”. Patheon is focusing initially on building organically in the UK and San Francisco, California but is also looking at acquisitions.

We continue to evaluate external options. That could offer us some unique capabilities that would take time and significant effort to build​”, Mark Kontny, president, global pharmaceutical development services at Patheon, told Outsourcing-Pharma.

Kontny said a “unique drug delivery technology that had specific expertise required​” could be a suitable acquisition but was “not at liberty to discuss​” the topic any further.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars